There is evidence to suggest that co-targeting IGF-1R could enhance melanoma response to MEK inhibitors [14, 17, 36–40], but the role of β-arrestin-biased signaling in dual targeting systems is not known. This evidence concerns the gene IGF1R and melanoma.